A nonsynonymous SNP in CNTNAP5 was recently identified in a genome-wide pharmacogenomic study as potentially influencing the effect of the drug risperidone on negative symptoms in schizophrenia (43). The gene discussed is CNTNAP5; the disease is schizophrenia.